Bioneer helps life science with R&D

The Contract Research Organisation Bioneer acts as an external R&D department for the life science ecosystem of companies involved in therapeutic development. The company is seeing substantial growth partly driven by its impressive journey as a specialty-CRO for recombinant protein solutions.

The specialty-CRO Bioneer has consolidated its role as R&D partner to the life science industry.

At the core of its activities, Bioneer translates science and know-how into technology platforms and processes that enable the industry to speed up discovery and development of new therapeutics.

”In essence, we help companies with two things: To create the necessary data to establish proof of concept for their compounds, and to produce recombinant proteins,” says Bioneer’s Chief Scientific Officer, Christian Clausen.

Bioneer in reality serves as an extended R&D department for its partners. The company makes its know-how, advanced disease models, technology platforms and laboratory facilities available to help produce, characterize and select the best drug candidates and the best formulations in the important R&D phases where multiple concepts are still being tried out.

”We are particularly proud of the role we play to Scandinavian biotech and pharmaceutical companies. We have worked alongside many of the biotech teams from they were first established, which is really optimal and gives us the ability to exchange ideas with their scientific experts and be part of the strategic choices they make,” says Christian Clausen.

The CSO explains that, although Bioneer has been the ‘go-to’ partner for all matters related to production of biologics and specialty proteins for more than three decades, the journey still continues.

”We have worked with so many challenging proteins over the years, most of which have been produced using our microbial platforms. Now we have expanded our capabilities and our laboratories to also handle production of more mainstream biologics using mammalian platforms,” says Christian Clausen.